A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced-stage Solid Tumors
In brief
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Key facts
- Study ID
- NCT07223125
- Run by
- Janssen Research & Development, LLC
- People needed
- 360
- Starts
- 2025-10-10
- Expected to finish
- 2028-08-15
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
- Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
You may not qualify if…
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
Where it is running
- AdventHealth Orlando — Orlando, Florida, United States (enrolling)
- NEXT Oncology — Irving, Texas, United States (enrolling)
- Centre Leon Berard — Lyon, France (enrolling)
- Gustave Roussy — Villejuif, France (enrolling)
- Severance Hospital Yonsei University Health System — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.